Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETECTIVE
NCT01376167Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Nov 2016
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of tafenoquine in Plasmodium vivax malaria (9 arms), sponsored by GSK. Primary endpoint: Number of Participants With Recurrence-free Efficacy at 6 Months Post Dose. Started Apr 2014; status: completed.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT01376167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01376167.